Dana-Farber Cancer Institute
44 Binney Street
Boston
Massachusetts
02115
United States
Tel: 617-632-3000
287 articles with Dana-Farber Cancer Institute
-
Foundation Medicine and Dana-Farber Present Data at ASCO20 Showing that Comprehensive Genomic Profiling Identified Co-Occurring Alterations that May Cause Treatment Resistance in Patients with METex14-altered NSCLC
5/29/2020
Alterations that cause skipping of exon 14 on the MET gene (METex14) are drivers of a type of lung cancer with a poor prognosis, but that is treatable with a recently approved MET inhibitor
-
Crown Bioscience Expands PDX Collection with Acquisition of Unique Models from Leading Academic Medical Centers
4/2/2020
Agreements with CoMotion at the University of Washington and Dana-Farber Cancer Institute add new prostate cancer and lymphoma models to the world’s largest PDX collection
-
It will combine MPM’s venture capital investment fundraising with Dana-Farber’s philanthropic fundraising for cancer research.
-
Clinical Catch-Up: February 10-14
2/17/2020
It was a very busy week for clinical trial news. Here’s a look. -
The study was in 55 patients who had an average of three previous treatment regimens. The results are promising enough that a Phase III trial is planned.
-
Vanderbilt Oncologists Publish Results of First Study to Demonstrate Clinical Utility of Resolution Liquid Biopsy Assay to Monitor Response and Resistance to Ensartinib
10/29/2019
New Journal of Thoracic Oncology publication concludes prospective application of technology may translate to improved outcomes for non-small cell lung cancer patients
-
Dana-Farber Cancer Institute Receives Largest Gift Ever, a Record-Breaking $63 Million
10/21/2019
100 percent of dollars raised by Pan-Mass Challenge riders to further advancements in cancer research and treatment
-
A new blood test in development from GRAIL, Inc. and studied by investigators at the Dana-Farber Cancer Institute has the ability to accurately screen for numerous types of cancer.
-
Dana-Farber Cancer Institute and the Jimmy Fund Debut New Visual Identity
9/26/2019
Dana-Farber Cancer Institute unveiled a new visual identity, modernizing its logo and that of the Jimmy Fund with a vivid blue and gold palette.
-
Resistance to immune checkpoint blocker drug linked to metabolic imbalance
9/25/2019
Cancer cells appear to adapt to treatment with checkpoint blocker drugs by altering a metabolic process, leading to shorter survival for patients
-
Hyundai Hope On Wheels Presents Dana-Farber Cancer Institute with $500,000 Hyundai Young Investigator And Scholar Hope Grant To Support Pediatric Cancer Research
9/20/2019
The Hyundai Hope On Wheels non-profit embarks on a nationwide tour this September during Childhood Cancer Awareness Month to award new grants for pediatric cancer, surpassing $160 million in lifetime funding for research. [20-September-2019] BOSTON , Sept. 20, 2019 /PRNewswire/ -- Hyundai Hope On Wheels® (HHOW), a 501(c)(3) non-profit organization supported by Hyu
-
Debbie's Dream Foundation to Host FREE Stomach Cancer Education Symposium and Live Webcast at Dana-Farber Cancer Institute
8/13/2019
Patients, families, and caregivers are invited to learn about gastric cancer and other cancer-related issues from oncology experts
-
Valvoline Instant Oil Change supports cancer research and care at Dana-Farber Cancer Institute
8/1/2019
53 Valvoline Instant Oil Change locations in New England are participating in A Chance for Kids & Families® program for the 6th consecutive year to raise money for the Jimmy Fund
-
The decision, which is likely to be appealed, will allow Dana-Farber to license the technology.
-
U.S. District Court Rules Dana-Farber Scientist is an Inventor on Six Critical Immunotherapy Patents
5/17/2019
The U. S. District Court ruled today that a Dana-Farber Cancer Institute scientist, Gordon Freeman, PhD, and another scientist, Clive Wood, PhD, are co-inventors on a series of cancer immunotherapy patents previously issued to a Japanese researcher and Japanese drug company, and ordered that the patents be corrected to name Freeman and Wood as inventors.
-
Resolution Liquid Biopsy Assay Outperforms Guardant360 in Retrospective Non-Small Cell Lung Carcinoma Comparison Pilot Study
4/1/2019
Scientists from Dana-Farber Cancer Institute present results demonstrating detection of more actionable oncogenic fusions today at AACR Annual Meeting
-
Cancer Research UK, a cancer research and awareness charity in the United Kingdom and Isle of Man, recently announced its latest Grand Challenge winners. This cancer research grant awards a series of £20 million wards to international, multidisciplinary teams that focus on unique and new approach...
-
The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
-
Dana-Farber Cancer Institute and Deerfield Collaborate to Create the Center for Protein Degradation
11/13/2018
The Center for Protein Degradation will build upon the work of Dana-Farber researchers Nathanael Gray, PhD and Eric Fischer, PhD
-
Joseph Eid, head of medical at BMS, said Empliciti in combination with pomalidomide and dexamethasone has provided proof that the medication can extend the time a patient can live without the worsening of his or her disease.